Sotera Health Company

Valuation Analysis

About the Company

Sotera Health Company en bref

Sotera Health Company (SHC) is currently trading at 13,79 € with a market capitalization of 3,9 Md €. The trailing P/E ratio stands at 38.59x, with a forward P/E of 14.88x. The 52-week range spans from 9,51 € to 17,30 €; the current price is 20.3% below the yearly high. Year-over-year revenue growth stands at +10.0%. The net profit margin stands at 9.91%.

💰 Dividende

Sotera Health Company currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Sotera Health Company (SHC) au consensus : Acheter. L'objectif de cours moyen est de 17,53 €, soit un potentiel de +27.12% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,95 € à 20,92 €.

Sotera Health Company : la thèse d'investissement en détail

Sotera Health Company (SHC) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10% pace year-over-year, suggesting the business model continues to find new customers and pricing power. The combination of a 55.26% gross margin and 31.26% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 27.12% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

The debt-to-equity ratio of 364.72% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The PEG ratio at 1.31 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 14.88x is meaningfully below the trailing 38.59x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 27.12% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (7.63%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Sotera Health Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.